The scientific focus adapted
to express the optimum potential
of your molecule

Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > VLDL-TG production test

hepatic VLDL-TG production test

First in vivo proof-of-concept of your compound’s impact on hepatic VLDL-TG production.

key benefits

  • In-house validated technique.
  • Impact of your compound on hepatic VLDL-TG production, an index of hepatic lipogenesis: determine whether increased fasting or fed circulating triglyceride levels come from increased hepatic production or from reduced clearance.
  • In vivo insights into your compound’s efficacy on cardiovascular parameters: VLDL-TG production by the liver is involved in the abnormal lipoprotein profile.
  • Suitable for large-scale screening purposes in vivo (20-30 compounds/week).

description and parameters

This technique is extremely useful for compounds designed to treat type 2 diabetes cardiovascular complications and/or dyslipidemia due to excessive hepatic lipogenesis.

Parameters evaluated

VLDL-TG production test
VLDL-TG production test

Add-on studies